Evaluation of the Effect and Mechanism of Sanhuang Ointment on MRSA Infection in the Skin and Soft Tissue via Network Pharmacology.
IL-17
MRSA
NF-κB
SSTI
Sanhuang ointment
network pharmacology
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
06
2023
accepted:
27
10
2023
medline:
13
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
Skin and soft tissue infection (SSTI) is a frequently encountered clinical disease, and Sanhuang ointment, a traditional Chinese medicine, is used to treat it. However, the pharmacological effect of Sanhuang ointment on SSTI and its underlying mechanism remains unclear. Here, we investigate the protective effect of Sanhuang ointment on Via network pharmacology, the active components and disease targets of Sanhuang ointment were screened and intersected for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. A rat model of skin and soft tissue infection was established, and pathological features were observed. Large, medium, and small-dose groups (1 g, 0.5 g, and 0.25 g/animal, with the total amount of Vaseline, dispensed 1 g/animal) of Sanhuang ointment were prepared and Mupirocin ointment was used as a positive control (0.5 g/animal, with the total amount of Vaseline, dispensed 1 g/animal). The expressions of key proteins of the IL-17/NF-κB signaling pathway and downstream inflammatory factors were analyzed by histomorphological analysis, enzyme-linked immunosorbent assay, polymerase chain reaction, and Western blotting. In all, 119 active components and 275 target genes of Sanhuang ointment were identified and intersected with MRSA infection-related genes via network pharmacology analysis, and 34 target genes of Sanhuang ointment were found to be involved in skin and soft tissue infections with MRSA. Sanhuang ointment (1 g/mouse) could effectively ameliorate histopathological changes and significantly inhibit the expression of key proteins involved in the IL-17/NF-κB signaling pathway and downstream inflammatory factors (p < 0.05). Sanhuang ointment has a protective effect on MRSA infection and inhibits inflammation by inhibiting the IL-17/NF-κB signaling pathway. Our findings are important for the secondary development and new drug development of Sanhuang ointment.
Identifiants
pubmed: 37954508
doi: 10.2147/IDR.S424746
pii: 424746
pmc: PMC10638900
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7071-7095Informations de copyright
© 2023 Pan et al.
Déclaration de conflit d'intérêts
Haibang Pan and Tianming Wang are co-first authors for this study. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nucleic Acids Res. 2015 Jan;43(Database issue):D789-98
pubmed: 25428349
Nat Chem Biol. 2008 Nov;4(11):682-90
pubmed: 18936753
Nat Immunol. 2017 May 18;18(6):612-621
pubmed: 28518156
Sci Signal. 2009 Oct 13;2(92):ra63
pubmed: 19825828
Microbiol Spectr. 2016 Aug;4(4):
pubmed: 27726817
Zhongguo Zhong Yao Za Zhi. 2007 Aug;32(16):1637-40
pubmed: 18027655
Biomed Pharmacother. 2021 Jan;133:110917
pubmed: 33217688
Chin J Nat Med. 2013 Mar;11(2):110-20
pubmed: 23787177
Inflammation. 2015;38(3):1071-9
pubmed: 25502067
Biophys J. 2015 Sep 15;109(6):1214-26
pubmed: 26276688
J Immunol. 2008 Aug 15;181(4):2799-805
pubmed: 18684971
Front Vet Sci. 2020 Jul 30;7:443
pubmed: 32851026
Eur J Med Chem. 2017 May 5;131:68-80
pubmed: 28288320
J Antimicrob Chemother. 2017 Sep 1;72(9):2454-2460
pubmed: 28595277
J Immunol. 2007 Oct 15;179(8):5462-73
pubmed: 17911633
J Pharm Biomed Anal. 2020 Feb 20;180:113089
pubmed: 31901737
Trends Immunol. 2017 May;38(5):310-322
pubmed: 28254169
Front Immunol. 2021 Jan 05;11:608976
pubmed: 33469458
Clin Microbiol Infect. 2018 Apr;24(4):429.e1-429.e5
pubmed: 28782651
Front Pharmacol. 2021 Jul 01;12:656115
pubmed: 34276360
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Methods Mol Biol. 2019;1960:139-147
pubmed: 30798528
Int J Biol Macromol. 2023 Sep 30;249:125762
pubmed: 37544228
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
Nat Rev Microbiol. 2019 Apr;17(4):203-218
pubmed: 30737488
Front Pharmacol. 2021 Jun 21;12:630834
pubmed: 34234668
Curr Protoc Bioinformatics. 2018 Jun;62(1):e52
pubmed: 29927080
Int Immunopharmacol. 2014 Apr;19(2):214-20
pubmed: 24503166
Clin Microbiol Rev. 2018 Sep 12;31(4):
pubmed: 30209034
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
IET Syst Biol. 2007 Jan;1(1):51-60
pubmed: 17370429
J Cheminform. 2014 Apr 16;6:13
pubmed: 24735618
Science. 2011 Apr 1;332(6025):65-8
pubmed: 21350122
Immunity. 2013 Oct 17;39(4):676-86
pubmed: 24120361
Int Rev Cell Mol Biol. 2018;335:41-84
pubmed: 29305014
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
J Exp Med. 1996 Jun 1;183(6):2593-603
pubmed: 8676080